| Gene | Score gda | Association Type | Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
0.080 | Biomarker | phenotype | BEFREE | Targeting the human blood coagulation-inducing protein tissue factor (TF) to the tumor vasculature to induce infarction and disrupt the blood vessels has proven to be an effective approach for tumor therapy. | 30222966 | 2018 | ||||
|
0.080 | Biomarker | phenotype | BEFREE | Correction: A tissue factor-cascade-targeted strategy to tumor vasculature: a combination of EGFP-EGF1 conjugation nanoparticles with photodynamic therapy. | 29707163 | 2018 | ||||
|
0.080 | Biomarker | phenotype | BEFREE | A tissue factor-cascade-targeted strategy to tumor vasculature: a combination of EGFP-EGF1 conjugation nanoparticles with photodynamic therapy. | 27793028 | 2017 | ||||
|
0.080 | Biomarker | phenotype | BEFREE | The fusion protein tTF-NGR consists of the extracellular domain of the thrombogenic human tissue factor (truncated tissue factor, tTF) and the peptide GNGRAHA (NGR), a ligand of the surface protein CD13 (aminopeptidase N), upregulated on endothelial cells of tumor vessels. tTF-NGR preferentially activates blood coagulation within tumor vasculature, resulting in tumor vessel infarction and subsequent tumor growth retardation/regression. | 24136410 | 2014 | ||||
|
0.080 | Biomarker | phenotype | BEFREE | Thus, targeting the TF pathway might be a promising treatment strategy for future glioblastoma therapies, by affecting both invading tumor cells and tumor vasculature. | 23384223 | 2013 | ||||
|
0.080 | Biomarker | phenotype | BEFREE | Inhibition of tumor growth by RGD peptide-directed delivery of truncated tissue factor to the tumor vasculature. | 16144936 | 2005 | ||||
|
0.080 | AlteredExpression | phenotype | BEFREE | The tumor cells infected by the vector synthesize and secrete the icon into the blood, and the blood-borne icon binds with high affinity and specificity to mouse tissue factor expressed on endothelial cells lining the lumen of the tumor vasculature and to human tissue factor expressed on the tumor cells. | 11593034 | 2001 | ||||
|
0.080 | AlteredExpression | phenotype | BEFREE | Endothelial monocyte activating polypeptide II (EMAP-II) is a tumor-derived cytokine with potent effects on endothelial cells in vitro and in vivo including upregulation of tissue factor and the sensitization of human melanoma to systemic TNF treatment via its effects on the tumor vasculature. | 10873516 | 2000 |